MCM
CUE icon

MAI Capital Management’s Cue Biopharma CUE Stock Holding History

MAI Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81 Hold
12
– – ﹤0.01% 4794
2025
Q4 		$107 Hold
12
– – ﹤0.01% 4157
2025
Q3 		$252 Hold
12
– – ﹤0.01% 3686
2025
Q2 		$239 Hold
12
– – ﹤0.01% 3851
2025
Q1 		$319 Hold
12
– – ﹤0.01% 3273
2024
Q4 		$382 Buy
+12
New +$451 ﹤0.01% 3321

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

MAI Capital Management's CUE Position: Q1 2026 in Review

MAI Capital Management held its Cue Biopharma (CUE) position steady in Q1 2026 at 12 shares worth $81. The position accounts for ﹤0.01% of the portfolio, ranked #4794.

MAI Capital Management first reported a position in CUE in Q4 2024 and has held it in 6 quarters since. The position peaked at $382 in Q4 2024. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • MAI Capital Management held 12 shares of Cue Biopharma worth $81 as of Q1 2026.
  • MAI Capital Management left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4794 holding.
  • MAI Capital Management first reported a position in Cue Biopharma in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Cue Biopharma position peaked at $382 in Q4 2024.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.